Q-omics provides the consensus-scored KLHL21 profile across patient tissues and cancer cell-line models. KLHL21 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, KLHL21 is differentially expressed in 13, with the highest sampling consensus in LIHC. Additionally, KLHL21 RNA expression shows 19,981 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight UVM, LIHC, and THYM as cancer lineages where KLHL21 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KLHL21 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KLHL21 survival associations across molecular data types. KLHL21 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (5) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KLHL21 RNA expression–survival associations across cancer types. High KLHL21 expression shows unfavorable associations in LGG, KICH and LIHC, but favorable associations in UVM, MESO and HNSC. The UVM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for KLHL21 RNA expression.
This table summarizes KLHL21 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 2. The strongest signals are observed in LIHC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for KLHL21. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KLHL21 shows lower tumor expression in BLCA, KIRC, BRCA and UCEC and higher tumor expression in LIHC and COAD. The LIHC box plot shows higher KLHL21 RNA expression in tumor versus normal tissue (log2 FC = +1.524, t-test p < 0.001).
This table shows molecular features associated with KLHL21 in patient tissues and cancer cell lines. In patient samples, KLHL21 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, KLHL21 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and LARGE_INTESTINE.
